A Brief History: The iGenoMed Consortium was created in 2012 to take full advantage of existing and emerging genomic technologies and apply these to powerful retrospective and prospective cohorts to better understand the biological differences between patients with IBD and to develop precision medicine approaches to improve diagnosis and treatment of IBD, and to advance our goal of disease prevention and/or achievement of durable remission.
Objectives: (1) Discover the biological heterogeneity that underlies the known clinical heterogeneity in IBD; (2) Develop genomic-based predictive tools to better diagnose and treat patients with (3) perform quantitative and qualitative assessment of physician and patient perceptions on different approaches to selecting IBD treatment options (i.e., current practice versus our approach); (4) identify obstacles – practical and regulatory – potentially hindering the implementation of our predictive tests.
Flagship Projects:
| Project 1 | Identifying biological heterogeneity in CD |
| Project 2 | Developing multi-omic tools to support rapid diagnosis of CD |
| Project 3 | iGenoMed-MTT: A Prospective Multi-omic Clinical Study of Response to Molecularly-Targeted Therapies in IBD <click here for more information> |
Founding Members:
| John D. Rioux, PhD (Leader) Institut de cardiologie de Montréal Université de Montréal | Alain Bitton, MD (Co-Leader) McGill University Health Centre |
| Sylvie Lesage, PhD Hôpital Maisonneuve-Rosemont Université de Montréal | Megan Levings, PhD Hôpital Maisonneuve-Rosemont Université de Montréal |
| Christine Des Rosiers, PhD Institut de cardiologie de Montréal Université de Montréal | Sophie Veilleux, PhD Université Laval |
| Brian White-Guay, MD Université de Montréal | Jean Lachaine, PhD Université de Montréal |
| Lawrence Joseph, PhD McGill University | Guy Charron, PhD Université de Montréal |
Selected Publications:
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease. Rioux JD, et al. medRxiv [Preprint]. 2024 Sep 22:2024.09.19.24314034. doi: 10.1101/2024.09.19.24314034. PMID: 39371119
Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures. Noiseux I, et al. BMC Gastroenterol. 2019 Feb 13;19(1):30. doi: 10.1186/s12876-019-0946-8. PMID: 30760205
Functional screen of inflammatory bowel disease genes reveals key epithelial functions. Ntunzwenimana JC, et al. Genome Med. 2021 Nov 11;13(1):181. doi: 10.1186/s13073-021-00996-7. PMID: 34758847
Serum Analyte Profiles Associated With Crohn’s Disease and Disease Location. Boucher G, et al. Inflamm Bowel Dis. 2021 Jun 9:izab123. doi: 10.1093/ibd/izab123.. PMID: 34106269
Comprehensive and Reproducible Untargeted Lipidomic Workflow Using LC-QTOF Validated for Human Plasma Analysis. Forest A, et al. J Proteome Res. 2018 Nov 2;17(11):3657-3670. doi: 10.1021/acs.jproteome.8b00270. Epub 2018 Oct 10. PMID: 30256116
Exploring the Use of a Participative Design in the Early Development of a Predictive Test: The Importance of Physician Involvement. Veilleux S, et al. Public Health Genomics. 2017;20(3):174-187. doi: 10.1159/000479289. Epub 2017 Aug 17.PMID: 28813717